Candel Therapeutics reports phase 3 prostate cancer biomarker data showing sustained immune remodeling after aglatimagene treatment

By Public Technologies
  • Candel Therapeutics disclosed new biomarker data from its completed phase 3 aglatimagene besadenovec trial in localized prostate cancer.
  • Results were presented at ASTRO 2026 on Sept. 29, 2026, following earlier phase 3 clinical outcome disclosures.
  • Analysis indicated treatment drove sustained immune remodeling in tumor tissue more than two years after therapy versus radiotherapy alone.
  • Findings supported earlier evidence of improved biopsy outcomes, underpinning the product’s proposed value proposition in localized prostate cancer.
  • Management positioned the data package as supportive of its planned Biologics License Application submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300805PRIMZONEFULLFEED9836237) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.